The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.
Apollo Therapeutics, a UK-based biopharmaceutical joint venture featuring pharmaceutical firms AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson, closed a $145m funding round today led by healthcare investment firm Patient Square Capital.
University College London’s UCL Technology Fund also took part in the round, as did Rock Springs Capital and Reimagined Ventures.
Apollo was established in late 2015 by AstraZeneca, GSK, Johnson & Johnson subsidiary Johnson & Johnson Innovation – JJDC, tech transfer offices Cambridge Enterprise and UCL Business, and Imperial…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
